Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Should all patients at high risk of atherothrombotic events receive dual antiplatelet therapy?

Nature Clinical Practice Cardiovascular Medicine volume 3, pages 416–417 (2006)Cite this article

boxed-textBhatt DL et al. for the CHARISMA Investigators (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354: 1706–1717

Until further investigation supports its use, long-term preventative dual antiplatelet therapy should be avoided in patients with established vascular disease and asymptomatic patients with cardiovascular risk factors

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. [No authors listed] (1994) Collaborative overview of randomised trials of antiplatelet therapy—I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 308: 81–106

  2. [No authors listed] (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348: 1329–1339

  3. Yusuf S et al.; The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345: 494–502

    Article  CAS  Google Scholar 

  4. Sabatine MS et al. (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352: 1179–1189

    Article  CAS  Google Scholar 

  5. Leon MB et al. (1998) A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 339: 1665–1671

    Article  CAS  Google Scholar 

  6. Pfeffer MA and Jarcho JA (2006) The charisma of subgroups and the subgroups of CHARISMA. N Engl J Med 354: 1744–1746

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Hannah Camm, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. cardiology fellow at Beth Israel Deaconess Medical Center and Harvard Medical School,

    Karen E Thomas & Duane S Pinto

  2. assistant professor of medicine at Harvard Medical School and the Director of the Cardiology Fellowship Training Program, Beth Israel Deaconess Medical Center, Boston, MA, USA

    Karen E Thomas & Duane S Pinto

Authors
  1. Karen E Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Duane S Pinto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Duane S Pinto.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Thomas, K., Pinto, D. Should all patients at high risk of atherothrombotic events receive dual antiplatelet therapy?. Nat Rev Cardiol 3, 416–417 (2006). https://doi.org/10.1038/ncpcardio0628

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0628

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing